Keunchil Park

1995–2025 年に発表

238
論文数
51,889
被引用数
106
h 指数
235
i10 指数

被引用数

Keunchil Park の年別被引用数1993 年: 被引用 1 件1996 年: 被引用 6 件1997 年: 被引用 18 件1998 年: 被引用 18 件1999 年: 被引用 14 件2000 年: 被引用 17 件2001 年: 被引用 23 件2002 年: 被引用 23 件2003 年: 被引用 16 件2004 年: 被引用 22 件2005 年: 被引用 29 件2006 年: 被引用 31 件2007 年: 被引用 38 件2008 年: 被引用 50 件2009 年: 被引用 105 件2010 年: 被引用 116 件2011 年: 被引用 156 件2012 年: 被引用 154 件2013 年: 被引用 245 件2014 年: 被引用 212 件2015 年: 被引用 260 件2016 年: 被引用 343 件2017 年: 被引用 484 件2018 年: 被引用 550 件2019 年: 被引用 1,715 件2020 年: 被引用 2,388 件2021 年: 被引用 2,949 件2022 年: 被引用 2,402 件2023 年: 被引用 1,818 件2024 年: 被引用 2,765 件2025 年: 被引用 1,346 件2026 年: 被引用 34 件1994〜1995 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 5,191 件、この内訳の 21.6%中国: 引用元論文 3,948 件、この内訳の 16.4%イタリア: 引用元論文 1,293 件、この内訳の 5.4%日本: 引用元論文 1,284 件、この内訳の 5.4%イギリス: 引用元論文 1,107 件、この内訳の 4.6%ドイツ: 引用元論文 1,014 件、この内訳の 4.2%フランス: 引用元論文 948 件、この内訳の 4%韓国: 引用元論文 929 件、この内訳の 3.9%スペイン: 引用元論文 867 件、この内訳の 3.6%カナダ: 引用元論文 682 件、この内訳の 2.8%オーストラリア: 引用元論文 548 件、この内訳の 2.3%オランダ: 引用元論文 547 件、この内訳の 2.3%
0%21.6%その他 23.5%

分野

  • Medicine71.9%
  • Biochemistry, Genetics and Molecular Biology21.2%
  • Immunology and Microbiology3.5%
  • Engineering0.5%
  • Computer Science0.5%
  • Chemistry0.5%
  • その他1.9%

トピック

  • Cancer Immunotherapy and Biomarkers12.2%
  • Lung Cancer Treatments and Mutations11%
  • Lung Cancer Research Studies6.1%
  • Lung Cancer Diagnosis and Treatment4.3%
  • Cancer Genomics and Diagnostics3.9%
  • Immunotherapy and Immune Responses2.7%
  • その他59.8%

共著者

全論文

検索で開く
  1. Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2019 被引用: 2,835

  2. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet 2016 被引用: 4,780

  3. KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Gregory Friberg, Piro Lito, Ramaswamy Govindan, Bob T. Li - New England Journal of Medicine 2020 被引用: 1,687

  4. Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma

    著者: , , , , , , , , , , , , , , , , , , , , - Nature Communications 2020 被引用: 1,337

  5. Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours

    著者: , , , , , , , , , , , , , , , , , , , , , , - British Journal of Cancer 2020 被引用: 912

  6. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

    著者: , , , , , , , , , , , , , , , , , - The Lancet 2016 被引用: 2,803

  7. Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Patricia Lorenzini, Meena Thayu, Roland E. Knoblauch, Byoung Chul Cho - Journal of Clinical Oncology 2021 被引用: 632

  8. Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2023 被引用: 347

  9. DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load

    著者: , , , , , , , , , - Nature Communications 2019 被引用: 563

  10. Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Karen L. Reckamp, Grace K. Dy, Jürgen Wolf, Benjamin Solomon, Gerald S. Falchook, Kevin Ebata, Michele Nguyen, Binoj C. Nair, Edward Y. Zhu, Luxi Yang, Xin Huang, Elizabeth Olek, S. Michael Rothenberg, Kōichi Goto, Vivek Subbiah - New England Journal of Medicine 2020 被引用: 836

  11. Artificial Intelligence–Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non–Small-Cell Lung Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2022 被引用: 282

  12. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet 2014 被引用: 1,308

  13. Analyses of non-coding somatic drivers in 2,658 cancer whole genomes

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Klev Diamanti, Nuno A. Fonseca, Abel González-Pérez, Qianyun Guo, Mark P. Hamilton, Nicholas J. Haradhvala, Hong Chen, Keren Isaev, Todd A. Johnson, Malene Juul, André Kahles, Abdullah Kahraman, Young-Wook Kim, Jan Komorowski, Kiran Kumar, Sushant Kumar, Donghoon Lee, Kjong-Van Lehmann, Yilong Li, Eric Minwei Liu, Lucas Lochovsky, Keunchil Park, Oriol Pich, Nicola D. Roberts, Gordon Saksena, Steven E. Schumacher, Nikos Sidiropoulos, Lina Sieverling, Nasa Sinnott-Armstrong, Chip Stewart, David Tamborero, José M. C. Tubío, Husen M. Umer, Liis Uusküla-Reimand, Claes Wadelius, Lina Wadi, Xiaotong Yao, Cheng‐Zhong Zhang, Jing Zhang, James E. Haber, Asger Hobolth, Marcin Imieliński, Manolis Kellis, Michael S. Lawrence, Christian von Mering, Hidewaki Nakagawa, Benjamin J. Raphael, Mark A. Rubin, Chris Sander, Lincoln D. Stein, Joshua M. Stuart, Tatsuhiko Tsunoda, David A. Wheeler, Rory Johnson, Jüri Reimand, Mark Gerstein, Ekta Khurana, Peter J. Campbell, Núria López-Bigas, PCAWG Drivers and Functional Interpretation Working Group, Federico Abascal, Samirkumar B. Amin, Gary D. Bader, Pratiti Bandopadhayay, Jonathan Barenboim, Rameen Beroukhim, Johanna Bertl, Keith A. Boroevich, Søren Brunak, Peter J. Campbell ほか 1,521 名 - Nature, Nat. 2020 被引用: 671

  14. Comprehensive molecular characterization of mitochondrial genomes in human cancers

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Fátima Al‐Shahrour, Malik Alawi, Monique Albert, Kenneth Aldape, Ludmil B. Alexandrov, Adrian Ally, Kathryn Alsop, Eva G. Álvarez, Fernanda Amary, Samirkumar B. Amin, Brice Aminou, Ole Ammerpohl, Matthew J. Anderson, Yeng Ang, Davide Antonello, Pavana Anur, Samuel Aparício, Elizabeth L. Appelbaum, Yasuhito Arai, Axel Aretz, Koji Arihiro, Shun‐ichi Ariizumi, Joshua Armenia, Laurent Arnould, L. Sylvia, Yassen Assenov, Gurnit Atwal, Sietse Aukema, J. Todd Auman, Miriam R. R. Aure, Philip Awadalla, Marta Aymerich, Gary D. Bader, Adrian Baez‐Ortega, Matthew H. Bailey, Peter J. Bailey, Miruna Balasundaram, Saianand Balu, Pratiti Bandopadhayay, Rosamonde E. Banks, Stefano Barbi, Andrew P. Barbour, Jonathan Barenboim, Jill S. Barnholtz‐Sloan, Hugh Barr, Elisabet Barrera, John Bartlett, Javier Bartolomé, Claudio Bassi, Oliver F. Bathe, Daniel Baumhoer, Prashant Bavi, Stephen B. Baylin, Wojciech Bażant, Duncan Beardsmore, Timothy A. Beck, Sam Behjati, Andreas Behren, Beifang Niu, Cindy Bell, Sergi Beltrán, Christopher C. Benz, Andrew Berchuck, Anke Bergmann, Erik N. Bergstrom, Benjamin P. Berman, Daniel M. Berney, Stephan H. Bernhart, Rameen Beroukhim, Mario Berríos ほか 1,241 名 - Nature Genetics 2020 被引用: 515

  15. First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Hossein Borghaei, Kenneth J. O’Byrne, Matthew D. Hellmann, Arteid Memaj, Faith E. Nathan, Judith Bushong, Phuong Tran, Julie R. Brahmer, Martin Reck - Journal of Thoracic Oncology 2021 被引用: 322

  16. First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion–Positive NSCLC

    著者: , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2023 被引用: 213

  17. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

    著者: , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2016 被引用: 1,175

  18. Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas

    著者: , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2017 被引用: 508

  19. Selpercatinib in Patients With RET Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial

    著者: , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2022 被引用: 205

  20. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Walburga Engel-Riedel, Stefan Hammerschmidt, Wolfgang Schütte, Konstantinos Syrigos, Jcm Ho, Kwok‐Hung Au, Silvia Novello, Andrea Ardizzoni, Giulia Pasello, Vanessa Gregorc, Alessandro Del Conte, Domenico Galetta, Toshiaki Takahashi, Kazuhiko Nakagawa, Makoto Nishio, Kiyotaka Yoh, Takashi Seto, Fumio Imamura, Toru Kumagai, Katsuyuki Hotta, Yasushi Goto, Yukio Hosomi, Hiroshi Sakai, Yuichi Takiguchi, Young Hak Kim, Takayasu Kurata, Hiroyuki Yamaguchi, Haruko Daga, Isamu Okamoto, Miyako Satouchi, Satoshi Ikeda, Kazuo Kasahara, Shinji Atagi, Koichi Azuma, Toru Kumagai, Keisuke Aoe, Toru Kumagai, Keisuke Aoe, Yoshitsugu Horio, Nobuyuki Yamamoto, Hiroshi Tanaka, Satoshi Watanabe, Naoyuki Nogami, Tomohiro Ozaki, Ryo Koyama, Tomonori Hirashima, Hiroyasu Kaneda, Keisuke Tomii, Yuka Fujita, Masahiro Seike, Naoki Nishimura, Terufumi Kato, Masao Ichiki, Hideo Saka, Katsuya Hirano, Yasuharu Nakahara, Shunichi Sugawara, Keunchil Park, Sang‐We Kim, Young Joo Min, Hyun Woo Lee, Jin‐Hyoung Kang, Ho Jung An, Ki Hyeong Lee, Jin-Soo Kim, Gyeong‐Won Lee, Sung Yong Lee, Aurelia Alexandru, Anghel Adrian Udrea, Óscar Juan ほか 31 名 - The Lancet Oncology 2019 被引用: 613

  21. Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor–Mutated Metastatic Non–Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722

    著者: , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2024 被引用: 153

  22. Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non–Small Cell Lung Cancer

    著者: , , , , , , , , , , , , , , , , , , , - JAMA Oncology 2021 被引用: 255

  23. Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2021 被引用: 267

  24. Integrative pathway enrichment analysis of multivariate omics data

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Dale W. Garsed, Mark Gerstein, Gad Getz, Abel González-Pérez, Qianyun Guo, Marta Gut, David Haan, Mark Hamilton, Nicholas J. Haradhvala, Arif Harmanci, Mohamed Helmy, Carl Herrmann, Julian M. Hess, Asger Hobolth, Ermin Hodzic, Chen Hong, Henrik Hornshøj, Keren Isaev, José M. G. Izarzugaza, Rory Johnson, Todd A. Johnson, Malene Juul, Randi Istrup Juul, Andre Kahles, Abdullah Kahraman, Manolis Kellis, Ekta Khurana, Jaegil Kim, Jong K. Kim, Young-Wook Kim, Jan Komorowski, Jan O. Korbel, Sushant Kumar, Andrés Lanzós, Michael S. Lawrence, Shantao Li, Kjong-Van Lehmann, Shantao Li, Xiaotong Li, Ziao Lin, Eric Minwei Liu, Lucas Lochovsky, Shaoke Lou, Tobias Madsen, Kathleen Marchal, Iñigo Martincorena, Alexander Martinez‐Fundichely, Yosef E. Maruvka, Patrick D. McGillivray, William Meyerson, Ferran Muiños, Loris Mularoni, Hidewaki Nakagawa, Morten Muhlig Nielsen, Keunchil Park, Kiejung Park, Jakob Skou Pedersen, Oriol Pich, Tirso Pons, Sergio Pulido-Tamayo, Benjamin J. Raphael, Iker Reyes-Salazar, Matthew A. Reyna, Esther Rheinbay, Mark A. Rubin, Carlota Rubio-Pérez, Radhakrishnan Sabarinathan, S. Cenk Şahinalp, Gordon Saksena, Leonidas Salichos ほか 1,360 名 - Nature Communications 2020 被引用: 236